HC Wainwright Reiterates "Buy" Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright's price target points to a potential upside of 241.88% from the stock's previous close.

Several other equities research analysts have also commented on GANX. Scotiabank initiated coverage on Gain Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price target for the company. Roth Mkm restated a "buy" rating and issued a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th. Finally, Roth Capital raised shares of Gain Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $8.20.

Gain Therapeutics Trading Up 2.2 %

Shares of GANX traded up $0.05 during mid-day trading on Monday, reaching $2.34. The company had a trading volume of 126,185 shares, compared to its average volume of 279,812. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.63. The firm has a fifty day simple moving average of $2.23 and a 200-day simple moving average of $2.01. The stock has a market cap of $62.07 million, a price-to-earnings ratio of -2.13 and a beta of 0.14. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04.

Remove Ads

Hedge Funds Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sprott Inc. purchased a new stake in shares of Gain Therapeutics during the fourth quarter valued at approximately $30,000. Benedict Financial Advisors Inc. purchased a new stake in Gain Therapeutics during the 4th quarter worth $35,000. Bridgeway Capital Management LLC purchased a new position in Gain Therapeutics in the 4th quarter valued at about $65,000. Northern Trust Corp boosted its position in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after buying an additional 39,642 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its stake in shares of Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock valued at $212,000 after acquiring an additional 44,750 shares in the last quarter. Hedge funds and other institutional investors own 11.97% of the company's stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.